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Background: Coronary artery disease (CAD) is one of the main fatal diseases all over
the world. CAD is a complex disease, which has multiple risk factors mechanisms. In re-
cent years, genome-wide association study (GWAS) had revealed single nucleotide poly-
morphism genes (SNPs) which were closely related with CAD risks. The relationship be-
tween long non-coding RNA (lncRNA) MALAT1 (metastasis-associated lung adenocarci-
noma transcript 1) and CAD risk is largely unknown. To our knowledge, this is the first
study which demonstrated the interaction effects of SNP–SNP and SNP–environment with
CAD risk. In general, our case–control study is to detect the association between MALAT1
(rs619586, rs4102217) SNPs and CAD risk.Methods: Three hundred and sixty-five CAD pa-
tients and three hundred and eighty-four matched control participants blood samples were
collected in Liaoning province, China. Two polymorphisms (rs619586, rs4102217) in lncRNA
MALAT1 were genotyped by KASP platform. Results: In a stratified analysis, we found that
non-drinkers with GC genotype and the recessive model of rs4102217 had higher CAD risk
(P=0.010, odds ratio (OR): 1.96, 95% confidence interval (CI) = 1.17–3.28; P=0.026, OR:
1.73, 95% CI = 1.07–2.79) and diabetes mellitus (DM) history group (P=0.010, OR: 4.07,
95% CI = 1.41–11.81; P=0.019, OR: 3.29, 95% CI = 1.22–8.88). In SNP–SNP interactions
analysis between MALAT1 and CAD risk, we found rs4102217 had an increase in smokers
(GG: OR: 2.04, 95% CI = 1.42–2.92; CC+GC: OR: 2.64, 95% CI = 1.64–4.26) and a de-
crease in drinkers (CC+GC: OR: 0.33, 95%CI= 0.20–0.55). Smokers withMALAT1 rs619586
AA genotype (OR: 2.20, 95% CI = 1.57–3.07) and GG+AG genotype (OR: 2.11, 95% CI =
1.17–3.81) had a higher risk of CAD. Moreover, drinkers with AA genotype (OR: 0.22, 95%
CI = 0.10–0.48) and GG+AG genotype (OR: 0.38, 95% CI = 0.22–0.65) had a lower risk of
CAD. According to the MDR software, MALAT1 rs4102217 polymorphism-smoking-drinking
was the best interaction model, which has higher risk of CAD (Testing Bal.ACC. = 0.6979).
Conclusion: Our study demonstrated that the GC genotype and the recessive model of
rs4102217 potentially increased CAD risk in some specific group.
Introduction
Currently, coronary artery disease (CAD) is one of the leading cause of deaths worldwide [1,2]. The 2017
China Reports of Cardiovascular Diseases showed that the prevalence of CAD disease in China is still on
the rise [3]. In next decades, CAD is expected to cause approximately 3.4 million deaths in China.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Multiple risk factors contribute to CAD development [4,5]. Recently, genome-wide association study (GWAS) has
revealed single nucleotide polymorphism genes (SNPs) which are related with CAD risk. As genetic inheritance is an
inevitable risk factor in the development of CAD, it is critical to identify the SNP locus of CAD risk [4,6–8].
Long non-coding RNA (lncRNA) is one of the most important members of non-coding RNA family. Recently, nu-
merous studies have reported that lncRNA plays a regulatory role in other complex diseases, such as cancer, ischemic
stroke, Alzheimer’s disease, and heart disease [9–14].
Particularly, MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) known as non-coding
nuclear-enriched abundant transcript 2 (NEAT2) is the one of the first found lncRNA with widely expression in
various mammalian species [14]. MALAT1 is located on chromosome 11q13.1, majorly expressed in nucleus and is
highly conserved. Moreover, it has high expression in various human tissues [15–18].
Many studies have shown that lncRNA MALAT1 was associated with CAD risk [19]. In 2012, Zhuo et al. [19]
demonstrated that rs619586A→G regulated the expression of XBP1, and ultimately prevented the proliferation and
metastasis of pulmonary artery endothelial cells. Vausort et al. [40] found that MALAT1 levels in peripheral blood
cells was significantly higher in acute myocardial infarction patients compared with controls. Wang et al. [20] found
that MALAT1 SNP rs619586 AG/GG genotypes may protect against the occurrence of CAD, but not rs11227209,
rs664589, and rs3200401. To our knowledge, no evidence demonstrates the relationship between MALAT1 SNP and
CAD risk. In addition, we further conducted SNP–SNP and SNP–environmental factors interaction analysis [20].
In summary, we conducted a case–control study, analyzed statistical methods with clinical data, and detected rela-
tionship between MALAT1 (rs619586, rs4102217) SNPs and CAD risk. The aim of the present study was to identify
predictive biomarkers for CAD risk and establish an experimental basis to improve understanding of the etiology and
the mechanism of CAD.
Materials and methods
Patients
The Ethical Committee of the Fourth Affiliated Hospital of the China Medical University approved this research
project and written informed consent was obtained. All clinical investigations have been conducted according to the
principles described in the Declaration of Helsinki. A total of 749 participants were recruited in the present study,
including 365 CADpatients and 384matched controls. All diagnoses weremade based on 2014AHA/ACC guidelines
for the management of NSTEACS and Third Universal Definition of Myocardial Infarction, with confirmation by
coronary angiography [21]. Coronary artery and Gensini score assessed the severity of CAD [22,23]. A total of 384
gender and age frequency-matched controls were included from a health screening program from the community of
the same area, Liaoning Province, China from 2012 to 2014. Peripheral venous blood specimens were collected from
participants and stored at −20◦C until use.
Exclusion criteria included history of malignancies, rheumatoid arthritis, and connective tissue diseases, organ
transplantation, and long-term use of immunosuppressive medication.
SNP selection and genotyping
Genetic polymorphisms were screened by HapMap database. Haploview 4.2 was used to select, and according to
Chinese Beijing Han population (CHB), unbalanced R2 value more than 0.8, and the minimum allele frequency
(Minor Allele Frequency, MAF) was greater than 5%. F-SNP software (http://compbio.cs.queensu.ca/F-SNP/) was
used to predict the possible functions of these selected sites. At last, we selected MALAT1 tagSNPs according to the
literature [24]. The most common SNPs onMALAT1 gene were two sites (rs4102217, rs619586).
Genomic DNA was extracted using a previously published method and diluted to working concentrations of 20
ng.l−1 for genotyping. The assay was performed byGeneCompany (Shanghai, China), using allele-specific PCR using
KASPar (KASP) reagents (LGC Genomics, Hoddesdon, U.K.). For quality control, we repeatedly genotyped 10% of
the total samples at one time. The concordance rate of these repeated samples reached 100%, which demonstrated
that the genotyping results were reliable.
Statistical analysis
Between-group differences of gender as well as the Hardy–Weinberg Equilibrium were compared by the χ2 test, and
ANOVA was conducted for age variability. Multivariate logistic regression with adjustments for age and gender was
used to show the association between selected gene polymorphisms with CAD risk. The haplotype of each gene was
analyzed using SHEsis software [25,26]. AllMALAT1 gene polymorphisms identified in the bestmodels of gene–gene
2 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 1 The association of lncRNA MALAT1 polymorphisms and CAD risk1
SNPs CON (%) CAD (%) CAD compared with CON
P2 OR (95% CI)
MALAT1 rs4102217
GG 275 (77.9) 243 (72.1) 1 (Ref)
GC 78 (22.1) 94 (27.9) 0.076 1.37 (0.97–1.94)
CC 11 (3.8) 8 (3.2) 0.705 0.84 (0.33–2.12)
CC+GC compared with GG 0.120 1.30 (0.93–1.82)
CC compared with GC+GG 0.575 0.77 (0.31–1.93)
C compared with G 0.233 1.20 (0.89–1.60)
PHWE2 0.068
MALAT1 rs619586
AA 309 (87.0) 293 (85.4) 1 (Ref)
AG 46 (13.0) 50 (14.6) 0.531 1.15 (0.75–1.77)
GG 2 (0.6) 1 (0.3) 0.667 0.59 (0.05–6.56)
GG+AG compared with AA 0.589 1.13 (0.74–1.72)
GG compared with G+AA 0.628 0.55 (0.05–6.12)
G compared with A 0.671 1.09 (0.73–1.63)
PHWE2 0.839
Abbreviations: CI, confidence interval; CON, control, OR, odds ratio; NCBI Ref, the reference frequencies of these polymorphisms in Beijing Han, China
in NCBI database.
1Using logistic regression adjusted by sex and age.
2Means Hardy−Weinberg Equilibrium in population.
interactions were calculated using MDR software (version 3.0.2). The combined effect of selected SNP–SNP interac-
tions in the best model was determined by multivariate logistic regression adjusted for age and gender. The associa-
tion between gene polymorphisms and clinical parameters was performed by χ2 test; the differences for the clinical
parameters amongst different polymorphism groups were compared by using t test. P-value <0.05 was considered
significant.
Results
The baseline characteristics of the subjects
The demographic characteristics of CAD and control subjects were shown in Supplementary Table S1. There was no
significant difference in the age (57.0+− 8.1 compared with 57.4+− 8.8 years) and gender (male 73.7% compared with
female 75.6%) between theCADand control groups. Therewere remarkable differences in the two groups of CAD risk
factors, including smoking, drinking, hypertension, diabetes, cerebrovascular disease, total cholesterol, triglyceride,
high-density lipoprotein, and low-density lipoprotein (P<0.05).
The association of SNPs in MALAT1 gene with CAD risk
We genotyped two polymorphisms of lncRNA MALAT1 gene (rs619586 and rs4102217) (Table 1). The two SNPs
were conformed to the Hardy–Weinberg Equilibrium. However, we did not find any relationship between the two
SNPs and CAD risk (P>0.05).
The association of MALAT1 polymorphisms with CAD risk stratified by
individual characteristics
Tominimize other CAD risk factors influences, we carried out a stratified analysis (Table 2 ). TheGCgenotype and the
recessive model of rs4102217 polymorphism showed stronger relations with higher CAD risk both in non-drinkers
(P=0.010, odds ratio (OR): 1.96, 95% confidence interval (CI)= 1.17–3.28; P=0.026, OR: 1.73, 95% CI= 1.07–2.79,
respectively) and in diabetes mellitus (DM) history group (P=0.010, OR: 4.07, 95% CI = 1.41–11.81; P=0.019, OR:
3.29, 95% CI = 1.22–8.88, respectively). We did not observe any changes in rs619586 (P>0.05).
The association between haplotype of MALAT1 SNPs and CAD risk
Haplotypes with a frequency less than 0.03 would be excluded from our analysis (Table 3). There were no significant
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Table 2 The association of lncRNA MALAT1 polymorphisms and CAD risk stratified by host characteristics
Variables Genotype CAD compared with CON P1 OR (95% CI)
MALAT1 rs4102217
Gender
Male GG 189/201 1 (Ref)
GC 65/58 0.319 1.23 (0.82–1.84)
CC 6/7 0.871 0.91 (0.30–2.76)
CC+GC compared with GG 0.372 1.19 (0.81–1.76)
CC compared with GC+GG 0.799 0.87 (0.29–2.61)
Female GG 54/74 1 (Ref)
GC 27/20 0.072 1.86 (0.95–3.68)
CC 2/4 0.696 0.71 (0.12–4.03)
CC+GC compared with GG 0.121 1.67 (0.87–3.18)
CC compared with GC+GG 0.545 0.59 (0.11–3.30)
Age (years)
≤60 GG 149/162 1 (Ref)
GC 53/44 0.251 1.31 (0.83–2.07)
CC 8/6 0.487 1.47 (0.50–4.37)
CC+GC compared with GG 0.198 1.33 (0.86–2.06)
CC compared with GC+GG 0.529 1.42 (0.48–4.18)
>60 GG 94/113 1 (Ref)
GC 41/34 0.164 1.47 (0.86–2.53)
CC 0/5 NA NA
CC+GC compared with GG 0.361 1.28 (0.76–2.17)
CC compared with GC+GG NA NA
Smoking
Ever smoker GG 168/144 1 (Ref)
GC 58/63 0.298 1.28 (0.80–2.04)
CC 7/4 0.568 1.45 (0.41–5.11)
CC+GC compared with GG 0.257 1.30 (0.83–2.03)
CC compared with GC+GG 0.627 1.37 (0.39–4.80)
Never smoker GG 75/131 1 (Ref)
GC 36/39 0.080 1.62 (0.94–2.77)
CC 1/7 0.185 0.24 (0.03–1.99)
CC+GC compared with GG 0.205 1.40 (0.83–2.36)
CC compared with GC+GG 0.146 0.21 (0.03–1.72)
Alcohol drinking
Drinker GG 65/151 1 (Ref)
GC 24/50 0.780 1.09 (0.61–1.92)
CC 2/5 0.909 1.11 (0.20–6.20)
CC+GC compared with GG 0.787 1.08 (0.62–1.88)
CC compared with GC+GG 0.986 1.02 (0.19–5.49)
Non-drinker GG 178/124 1 (Ref)
GC 70/28 0.010 1.96 (1.17–3.28)
CC 6/6 0.557 0.70 (0.21–2.30)
CC+GC compared with GG 0.026 1.73 (1.07–2.79)
CC compared with GC+GG 0.396 0.60 (0.18–1.96)
HBP
Yes GG 135/89 1 (Ref)
GC 54/23 0.168 1.48 (0.85–2.60)
CC 4/2 0.945 1.07 (0.18–6.23)
CC+GC compared with GG 0.173 1.46 (0.85–2.52)
CC compared with GC+GG 0.941 1.07 (0.19–6.05)
NO GG 107/186 1 (Ref)
GC 40/55 0.383 1.24 (0.77–2.00)
CC 4/9 0.647 0.75 (0.22–2.57)
CC+GC compared with GG 0.498 1.17 (0.74–1.85)
CC compared with GC+GG 0.611 0.73 (0.22–2.45)
Continued over
4 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 2 The association of lncRNA MALAT1 polymorphisms and CAD risk stratified by host characteristics (Continued)
Variables Genotype CAD compared with CON P1 OR (95% CI)
DM
Yes GG 62/39 1 (Ref)
GC 29/5 0.010 4.07 (1.41–11.81)
CC 0/1 NA NA
CC+GC compared with GG 0.019 3.29 (1.22-8.88)
CC compared with GC+GG NA NA
No GG 181/235 1 (Ref)
GC 65/73 0.412 1.18 (0.80–1.74)
CC 8/10 0.884 1.07 (0.41–2.81)
CC+GC compared with GG 0.426 1.16 (0.80–1.69)
CC compared with GC+GG 0.963 1.02 (0.40–2.65)
LDL
High GG 44/56 1 (Ref)
GC 14/16 0.787 1.12 (0.49–2.59)
CC 2/2 0.801 1.29 (0.18–9.59)
CC+GC compared with GG 0.732 1.15 (0.52–2.54)
CC compared with GC+GG 0.819 1.26 (0.17–9.26)
Normal GG 174/211 1 (Ref)
GC 65/60 0.183 1.32 (0.88–1.98)
CC 5/9 0.489 0.68 (0.22–2.06)
CC+GC compared with GG 0.293 1.23 (0.83–1.82)
CC compared with GC+GG 0.414 0.63 (0.21–1.91)
Low GG 12/6 1 (Ref)
GC 8/2 0.564 1.84 (0.23–14.68)
CC 0/0 NA NA
CC+GC compared with GG 0.564 1.84 (0.23–14.68)
CC compared with GC+GG NA NA
MALAT1 rs619586
Gender
Male AA 225/223 1 (Ref)
AG 33/36 0.699 0.91 (0.54–1.50)
GG 1/1 0.923 1.15 (0.07–18.62)
GG+AG compared with AA 0.709 0.91 (0.55–1.50)
GG compared with AG+AA 0.956 1.08 (0.07-17.50)
Female AA 68/86 1 (Ref)
AG 17/10 0.069 2.19 (0.94–5.11)
GG 0/1 NA NA
GG+AG compared with AA 0.103 1.99 (0.87–4.53)
GG compared with AG+AA NA NA
Age (years)
≤60 AA 175/184 1 (Ref)
AG 29/25 0.487 1.23 (0.69–2.18)
GG 1/1 0.993 1.01 (0.06–16.35)
GG+AG compared with AA 0.493 1.22 (0.69–2.15)
GG compared with AG+AA 0.990 1.02 (0.06–16.40)
>60 AA 118/125 1 (Ref)
AG 21/21 0.898 1.04 (0.54–2.01)
GG 0/1 NA NA
GG+AG compared withAA 0.995 1.00 (0.52–1.91)
GG compared with AG+AA NA NA
Smoking
Ever smoker AA 205/159 1 (Ref)
AG 30/24 0.983 0.99 (0.56–1.77)
GG 1/1 0.949 0.91 (0.06–14.86)
GG+AG compared with AA 0.970 0.99 (0.56–1.75)
GG compared with AG+AA 0.928 0.88 (0.05–14.28)
Continued over
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Table 2 The association of lncRNA MALAT1 polymorphisms and CAD risk stratified by host characteristics (Continued)
Variables Genotype CAD compared with CON P1 OR (95% CI)
Never smoker AA 88/150 1 (Ref)
AG 20/22 0.186 1.57 (0.81–3.05)
GG 0/1 NA NA
GG+AG compared with AA 0.235 1.49 (0.77–2.89)
GG compared with AG+AA NA NA
Alcohol drinking
Drinker AA 78/174 1 (Ref)
AG 13/26 0.800 1.10 (0.53–2.26)
GG 0/1 NA NA
GG+AG compared with AA 0.884 1.06 (0.52–2.16)
GG compared with AG+AA NA NA
Non-drinker AA 215/135 1 (Ref)
AG 37/20 0.481 1.24 (0.68–2.27)
GG 1/1 0.834 0.74 (0.04–12.70)
GG+AG compared with AA 0.515 1.22 (0.67–2.20)
GG compared with AG+AA 0.800 0.69 (0.04–11.75)
HBP
Yes AA 165/90 1 (Ref)
AG 31/16 0.957 1.02 (0.53–1.98)
GG 0/2 NA NA
GG+AG compared with AA 0.758 0.90 (0.48–1.72)
GG compared with AG+AA NA NA
No AA 127/219 1 (Ref)
AG 19/30 0.814 1.08 (0.58–2.01)
GG 1/0 NA NA
GG+AG compared with AA 0.695 1.13 (0.61–2.09)
GG compared with AG+AA NA NA
DM
Yes AA 71/39 1 (Ref)
AG 17/7 0.778 1.15 (0.43–3.12)
GG 0/0 NA NA
GG+AG compared with AA 0.778 1.15 (0.43–3.12)
GG compared with AG+AA NA NA
No AA 222/269 1 (Ref)
AG 33/39 0.997 1.00 (0.61–1.65)
GG 1/2 0.802 0.73 (0.07–8.22)
GG+AG compared with AA 0.959 0.99 (0.60–1.61)
GG compared with AG+AA 0.768 0.70 (0.06–7.78)
LDL
High AA 56/54
AG 6/15 0.065 0.38 (0.14–1.06)
GG 1/1 0.936 0.89 (0.05–14.86)
GG+AG compared with AA 0.072 0.41 (0.16–1.08)
GG compared with AG+AA 1.000 1.00 (0.06–16.55)
Normal AA 204/246
AG 36/29 0.128 1.50 (0.89–2.54)
GG 0/1 NA NA
GG+AG compared with AA 0.159 1.46 (0.86–2.45)
GG compared with AG+AA NA NA
Low AA 16/6
AG 4/2 0.782 0.74 (0.09–8.37)
GG 0/0 NA NA
GG+AG compared with AA 0.782 0.74 (0.09–6.37)
GG compared with AG+AA NA NA
Abbreviations: CON, control; HBP, high blood pressure; LDL, low-density lipoprotein.
1Using Logistic Regression adjusted by gender and age.
Values in bold represent statistical significance.
6 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 3 The association of haplotype of MALAT1 gene and CAD risk
Haplotype Case (%) Control (%) P OR (95% CI)
CA 88.83 (0.135) 97.97 (0.141) 0.838 0.97 (0.71–1.32)
GA 520.17 (0.788) 549.03 (0.789) 0.560 1.08 (0.83–1.41)
GG 39.83 (0.060) 48.97 (0.070) 0.508 0.86 (0.56–1.33)
Used SHEsis software for analysis (http://analysis.bio-x.cn/).
Table 4 The interaction of three MALAT1 polymorphisms with environmental factors in CAD risk
Smoking Drinking
Never Smoker Ever Smoker Non-drinker Drinker
MALAT1 rs4102217
GG Case/control 75/131 168/144 178/124 65/151
OR (95% CI) 1 (Ref) 2.04 (1.42–2.92) 1 (Ref) 0.30 (0.21—0.43)
CC+GC Case/control 37/46 65/43 76/34 26/55
OR (95% CI) 1.41 (0.84–2.36) 2.64 (1.64–4.26) 1.56 (0.98–2.48) 0.33 (0.20–0.55)
Pinteraction=0.825 Pinteraction=0.207
OR = 0.93, 95% CI = 0.47–1.84 OR = 0.624, 95% CI = 0.30–1.30
MALAT1 rs619586
AA Case/control 88/150 205/19 215/135 78/174
OR (95% CI) 1 (Ref) 2.20 (1.57–3.07) 1 (Ref) 0.22 (0.10–0.48)
GG+AG Case/control 20/23 31/25 38/21 13/27
OR (95% CI) 1.48 (0.77–2.85) 2.11 (1.17–3.81) 1.41 (0.84–2.37) 0.38 (0.22–0.65)
Pinteraction=0.355 Pinteraction=0.753
OR = 0.66, 95% CI = 0.28–1.58 OR = 0.86, 95% CI = 0.34–2.18
P for interaction used logistic regession adjusted by gender, age.
Table 5 Gene–gene interaction models for MALAT1 two polymorphisms for CAD risk by MDR analysis
Model Training Bal. Acc. Testing Bal. Acc. Sign Test (P) CV Consistency P for permutation test
Drinking 0.6598 0.6601 10 (0.0010) 10/10 0.0000–0.0010
Smoking-Drinking 0.6790 0.6789 10 (0.0010) 10/10 0.0000–0.0010
MALAT1
rs4102217-smoking-drinking1
0.6995 0.6979 10 (0.0010) 10/10 0.0000–0.0010
MALAT1
rs4102217-MALAT1
rs619586-smoking-drinking
0.7054 0.6900 10 (0.0010) 10/10 0.0000–0.0010
The best model was selected as the one with the maximum testing accuracy and maximum CV consistency.
1In this study, the best interaction model was the three-factor model including MALAT1 rs4102217 polymorphism-smoking-drinking.
differences in the haplotype analysis (P>0.05).
Multidimensional analysis of SNP–SNP interactions between MALAT1 and
CAD risk
To investigate SNP–SNP interactions between MALAT1 and CAD risk, multiple logistic regression analysis was em-
ployed (Table 4). We found rs4102217 had interactions with smokers (GG: OR: 2.04, 95% CI = 1.42–2.92; CC+GC:
OR: 2.64, 95% CI = 1.64–4.26) and drinkers (CC+GC: OR: 0.33, 95% CI = 0.20–0.55). We also found MALAT1
rs619586 AA genotype (OR: 2.20, 95% CI = 1.57–3.07) and GG+AG genotype (OR: 2.11, 95% CI = 1.17–3.81) had
higher risks of CAD in smokers. In addition, rs619586 AA genotype (OR: 0.22, 95% CI = 0.10–0.48) and GG+AG
genotype (OR: 0.38, 95% CI= 0.22–0.65) had lower risks of CAD in drinkers. Meanwhile, MDR software was used to
further investigate the locus–locus interactions of MALAT1 and CAD risk (Table 5). We found that the three factors
model,MALAT1 rs4102217 polymorphism-smoking-drinkingwas the best interactionmodel. Themaximum testing
accuracy was 0.6979, the maximum CV consistency was 10/10. Furthermore, we conducted cumulative effect of the
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Table 6 Cumulative effect of the interacting factors of MALAT1 SNPs on CAD
Number of interacting genotypes Total population
Cases/controls P1 value OR (95% CI)
MALAT1 rs41022173-rsMALAT1
rs619568-smoking-drinking
0 56/75 1 (Ref)
1 134/92 0.009 1.84 (1.17–2.90)
2 105/127 0.904 0.97 (0.60–1.58)
3 31/51 0.266 0.70 (0.38–1.31)
4 4/3 0.610 1.50 (0.32–7.13)
Ptrend=0.198
1, Adjusted by sex and age.
Values in bold represent statistical significance.
interacting factors of MALAT1 SNPs on CAD risk (Table 6). MALAT1 rs4102217 polymorphism-smoking-drinking
was considered as an integrated risk factor. CAD patients were divided into five groups of risks: group 1:0 risk geno-
type; group 2: 1 risk genotype; group 3: 2 risk genotypes; group 4: 3 risk genotypes; and group 5: 4 risk genotypes.
After adjustment of gender and age, group 2 had a higher risk of CAD (P=0.009, OR: 1.84, 95% CI = 1.17–2.90).
The association between MALAT1 polymorphisms and clinical parameters
To analyze the relationship between clinical parameters and genetic polymorphisms, themain genetic polymorphisms
model was selected. In general, if the P-value of the dominant model was less than the recessive model, then the
dominant model was selected, otherwise the recessive model was selected (Table 7). In our data, the dominant gene
model was selected both in MALAT1 rs4102217 and in MALAT1 rs619586. We found that MALAT1 rs4102217
CC+GC genotype was higher in uric acid in both qualitative analysis (P=0.014) and quantitative analysis (359.35
+− 109.90 compared with 327.06 +− 115.38 μmol/l; P=0.015). Moreover, we found that the wild-type triglyceride
for MALAT1 rs619586 was lower than the mutation (P=0.003), and the content was significantly lower (1.82 +−
1.39 compared with 3.12 +− 3.58 mmol/l; P=0.017). High-density lipoprotein in wild-type is significantly higher
than mutation-type for MALAT1 rs619586 (1.02 +− 0.29 compared with 0.92 +− 0.24 mmol/l, P=0.032). There was a
dramatic increase in uric acid in the wild-type than in the mutation-type (342.75 +− 101.42 compared with 385.04 +−
159.87 μmol/l, P=0.013). In addition, we analyzed the association of MALAT1 SNPs with severity of coronary artery
by analyzing numbers of coronary artery lesion branches and Gensini score. But there was no statistical significance
(P>0.05).
Discussion
In our research, we found the GC genotype and the recessive model of rs4102217 polymorphism showed stronger
relations with higher CAD risk both in non-drinkers and in DM history groups. In SNP–SNP interactions analysis
betweenMALAT1 and CAD risk,MALAT1 rs4102217 polymorphism-smoking-drinking had a higher CAD risk.We
also found that uric acid was higher in MALAT1 rs4102217 CC+GC genotype. Moreover, the wild-type of triacyl-
glyceride for MALAT1 rs619586 was lower than the mutation-type. There were dramatic increases in uric acid and
HDL in the wild-type than in the mutation-type.
MALAT1 is located on chromosome 11q13.1, and its length is 8.1 kb. MALAT-1 is a real non-coding RNA. Due
to the lack of enough ORF and the location of its nucleus, the lncRNA cannot encode protein. In recent years, asso-
ciation between lncRNA, MALAT1, and cardiovascular diseases are popular [20,27–29]. Previous study showed that
MALAT1 expression in atherosclerotic plaques was down-regulated and negatively related to age when compared
with non-atherosclerotic artery specimens from CAD patients [30]. Another research found that peripheral matrix
rather than the cell origin in CAD determined the classification of arterial and coronary vascular smooth muscle.
The peripheral matrix lncRNA MALAT1 was sensitive in the peripheral matrix and can regulate the proliferation
and migration of arterial and coronary vascular smooth muscle [31]. Thus, above evidences suggested that MALAT1
might be closely related to the development of CAD.
Rs4102217 is a variant of G/C in the exon region of MALAT1 gene, which has not been reported yet. In our data, we
found that there was no relationship in main effect analysis. However, in stratified analysis, the GC genotype and the
recessive model of rs4102217 polymorphism showed stronger relations with higher CAD risk both in non-drinkers
8 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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Table 7 The association of MALAT1 SNPs and clinical features
Variation Wild-type Mutated-type Wild-type Mutated-type P
MALAT1 rs4102217
Smoking P=0.327
No 75 (30.9) 37 (36.3) / / /
Yes 168 (69.1) 65 (63.7) / / /
Drinking P=0.809
No 178 (73.3) 76 (74.5) / / /
Yes 65 (26.7) 26 (25.5) / / /
HBP P=0.854
No 107 (44.2) 44 (43.1) / / /
Yes 135 (55.8) 58 (56.9) / / /
Diabetes P=0.575
No 181 (74.5) 73 (71.6) / / /
Yes 62 (25.5) 29 (28.4) / / /
Cerebrovascular disease P=0.570
No 208 (86.0) 90 (88.2) / / /
Yes 34 (14.0) 12 (11.8) / / /
Hyperlipidemia P=0.521
No 114 (46.9) 44 (43.1) / / /
Yes 129 (53.1) 58 (56.9) / / /
Blood Glucose P=0.747 8.20 +− 4.14 8.53 +− 5.10 0.538
Normal 80 (33.8) 32 (31.7)
High 156 (65.8) 69 (68.3)
Low 1 (0.4) 0 (0)
Total cholesterol P=0.719 4.43 +− 1.19 4.55 +− 1.21 0.385
Normal 178 (77.4) 71 (75.5)
High 52 (22.6) 23 (24.5)
Triacylglyceride P=0.373 1.90 +− 1.58 2.29 +− 2.58 0.168
Normal 193 (83.9) 75 (79.8)
High 37 (16.1) 19 (20.2)
High-density lipoprotein P=0.846 0.99 +− 0.27 0.98 +− 0.29 0.708
Normal 105 (45.7) 46 (48.9)
High 2 (0.9) 1 (1.1)
Low 123 (53.5) 47 (50.0)
Low-density lipoprotein P=0.510 2.94 +− 1.05 2.91 +− 0.84 0.795
Normal 174 (75.7) 70 (74.5)
High 44 (19.1) 16 (17.0)
Low 12 (5.2) 8 (8.5)
Urea nitrogen P=0.980 6.27 +− 3.47 6.44 +− 5.18 0.732
Normal 213 (89.1) 91 (89.2)
High 26 (10.9) 11 (10.8)
Creatinine P=0.497 89.93 +− 50.92 88.80 +− 31.66 0.835
Normal 227 (95.0) 95 (93.1)
High 12 (5.0) 7 (6.9)
Uric acid P=0.014 359.35 +− 109.90 327.06 +− 115.38 0.015
Normal 190 (79.2) 92 (90.2)
High 50 (20.8) 10 (9.8)
Coronary artery lesions P=0.307
One 57 (27.9) 19 (21.3) / / /
Two 39 (19.1) 23 (25.8) / / /
Three or more 108 (52.9) 47 (52.8) / / /
Gensini score 54.30 +− 36.03 50.98 +− 31.89 0.458
MALAT1 rs619586
Smoking P=0.192
No 88 (30.0) 20 (39.2) / / /
Yes 205 (70.0) 31 (60.8) / / /
Drinking P=0.866
Continued over
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Table 7 The association of MALAT1 SNPs and clinical features (Continued)
Variation Wild-type Mutated-type Wild-type Mutated-type P
No 215 (73.4) 38 (74.5) / / /
Yes 78 (26.6) 13 (25.5) / / /
HBP P=0.569
No 127 (43.5) 20 (39.2) / / /
Yes 165 (56.5) 31 (60.8) / / /
Diabetes P=0.169
No 222 (75.8) 34 (66.7) / / /
Yes 71 (24.2) 17 (33.3) / / /
Cerebrovascular disease P=0.077
No 256 (87.7) 40 (78.4) / / /
Yes 36 (12.3) 11 (21.6) / / /
Hyperlipidemia P=0.434
No 138 (47.1) 21 (41.2) / / /
Yes 155 (52.9) 30 (58.8) / / /
Blood glucose P=0.169 8.06 +− 3.80 9.10 +− 6.60 0.282
Normal 90 (31.5) 20 (40.0)
High 195 (68.2) 29 (58.0)
Low 1 (0.3) 1 (2.0)
Total cholesterol P=0.619 4.49 +− 1.14 4.49 +− 1.56 0.965
Normal 208 (75.4) 37 (78.7)
High 68 (24.6) 10 (21.3)
Triacylglyceride P=0.003 1.82 +− 1.39 3.12 +− 3.58 0.017
Normal 236 (85.5) 32 (68.1)
High 40 (14.5) 15 (31.9)
High-density lipoprotein P=0.150 1.02 +− 0.29 0.92 +− 0.24 0.032
Normal 136 (49.3) 17 (36.2)
High 4 (1.4) 0 (0)
Low 136 (49.3) 30 (63.8)
Low-density lipoprotein P=0.572 2.97 +− 1.00 2.75 +− 1.08 0.159
Normal 204 (73.9) 36 (76.6)
High 56 (20.3) 7 (14.9)
Low 16 (5.8) 4 (8.5)
Urea nitrogen P=0.077 6.22 +− 3.68 6.84 +− 5.81 0.316
Normal 261 (90.6) 42 (82.4)
High 27 (9.4) 9 (17.6)
Creatinine P=0.451 90.11 +− 48.60 87.03 +− 29.51 0.662
Normal 273 (94.8) 47 (92.2)
High 15 (5.2) 4 (7.8)
Uric acid P=0.952 342.75 +− 101.42 385.04 +− 159.87 0.013
Normal 239 (82.7) 42 (82.4)
High 50 (17.3) 9 (17.6)
Coronary artery lesions P=0.535
One 66 (26.7) 14 (31.1) / / /
Two 49 (19.8) 11 (24.4) / / /
Three or more 132 (53.4) 20 (44.4) / / /
Gensini score 52.54 +− 33.26 54.48 +− 39.14 0.727
and in DM history groups. It could be used as a genetic locus to predict CAD risk. Rs619586 is the mutation of
nucleotides A/G in the promoter region. Zhou et al. found thatMALAT1 rs619586A/G is closely related to pulmonary
hypertension risk [19]. Comparedwith the A loci causing PAH, theG genotype carrier has a lower risk. Another study
pointed out that the rs619586 A/G mutation can directly up-regulate the expression of XBP1, and ultimately prevent
the proliferation andmetastasis of vascular endothelial cells [19]. Report fromWang et al. [20] suggested that rs619586
AG/GG genotypes and G allele were associated with a reduced risk of CAD. Li et al. [28] demonstrated that the
functional MALAT1 polymorphism rs619586 A/G was significantly associated with CHD susceptibility in Chinese
10 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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population. However, we did not find any association with CAD risk in rs619586 in main effect analysis. While, we
obtained significant results in further interaction analysis of SNP–SNP and SNP–environment.
CAD is a complex disease involving multiple genes, multiple factors, such as age, sex, smoking, drinking,
blood lipids, diabetes, and hypertension [32]. The development of CAD can not only be explained by SNPs. We
conducted logistic regression analysis and MDR software analysis respectively to investigate the association between
the SNP–SNP or SNP–environment interaction effects of MALAT1 and CAD risk [24,31,33,34]. Our data indicated
that MALAT1 rs4102217 interacted with smokers and drinkers. MALAT1 rs619586 AA genotype and GG+AG geno-
type showed an elevated risk of CAD in smokers. AA genotype and GG+AG genotype showed a reduced risk of CAD
in drinkers. To further investigate the relationship, MDR software was used to calculate the best prediction model
and the prediction error of the training samples was measured by the test sample (the rest of the sample), while the
evaluation for the size of the cross-validation consistency was used. We found that the three factors model, MALAT1
rs4102217 polymorphism-smoking-drinking was the most predictive model for the CAD risk, which had the maxi-
mum test accuracy and the maximum cross-validation consistency amongst the analysis results. They indicated that
SNP–environment interaction effects were better to predict CAD than SNP alone.
In our research, we also analyzed the relationship between the polymorphism and clinical features. MALAT1
rs4102217 wild-type had more likely to suffer higher uric acid both qualitatively and quantitatively. For MALAT1
rs619586, we found the wild-type genotype carriers hadmore likely in high triglyceride and low high-density lipopro-
tein. Moreover, we used the numbers of coronary artery and Gensini score to assess coronary severity in our study.
However, we did not find any differences.
Our research indicated that MALAT1may be associated with the incidence of CAD, but currently, the mechanism
of MALAT1 in CAD risk is not yet clear. MALAT1 probably performs its functions in two ways: alternative splicing
or gene transcription regulation [35–37]. Lamond and Spector [38] found that MALAT-1 regulates the expression
of post-transcriptional genes by regulating the distribution of SR (serine/arginine-rich) proteins which are rich in
the nuclear spots. Moreover, MALAT-1 regulates the pre-mRNA (precursor messenger) level of SR protein. Weiner
et al. [39] found that MALAT-1 alternatively regulates splicing by SR protein, including SRSF1, SRSF2, and SRSF3.
Knocking down MALAT-1 will lead to ectopic of various splicing factors such as SF1, U2AF65, and SF3a60 [39].
Overexpression of SRSF1 results in alternative splicing results, which is similar to those obtained by knocking down
MALAT1.
In summary, our study demonstrated that the polymorphisms (rs4102217, rs619586) of MALAT1 were associated
with the CAD risk in Chinese population, which might predict CAD risk in the future.
Limitations
Several limitations remained in our study: first, the sample size was relatively not sufficiently large in our study. The
populations selected in our research were all Han people in Liaoning province. So the results of our study need to
be validated in larger samples, other regions, and ethnic groups. Second, we only selected two sites of MALAT1. We
need to test more sites to verify the association of CAD and MALAT1.
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